tbuckley/cabot-search huggingface dataset:
AB1213 Anti TNF dosage reduction response in juvenile idiopathic arthritis associated to enthesitis patients who achieved clinical remission:
Authors: V. Torrente-Segarra, X. Juanola, R. Bou, S. Ricart, J. Antόn, J.M. Nolla
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Juvenile Idiopathic Arthritis (JIA) related to Enthesitis (JIA-ERA) it means 10-15% of all JIA patients. Once NSAID, methotrexate and corticosteroids fail to control disease activity, the use of an anti-TNF alpha is recommended. Once clinical remission is reached, the amount of time recommended to mantain the anti-TNF is unknown. <h3>Objectives</h3> To describe the response to the reduction of anti-TNF dosage in JIA-ERA patients who achieved clinical remission with medication. <h3>Methods</h3> We describe 4 cases of JIA-ERA who received anti-TNF treatment and reached clinical remission. After, at least, 12 months of clinical remission, anti-TNF dosage was tappered by increasing the week interval of anti-TNF administration (50mg every 2 weeks in etanercept; 40mg every 4 weeks in adalimumab). We considered clinical remission with medication (Wallace criteria) those patients who had inactive disease for 6 months: no arthritis, no enthesitis, no inflammatory low back pain, normal CPR and ESR, and VAS Physician=0). We collected following data: clinical features, age of onset, clinical features, B27 presence, acute phase reactants at onset, initial treatment, first DMARD, anti-TNF, remission time prior to dosage reduction, total time in remission with tappered dosage. We tappered anti-TNF treatment to those patients who stayed at least 12 months in clinical remission. <h3>Results</h3> The table shows patients' features. <h3>Conclusions</h3> The reduction of anti-TNF dosage seems a right decision in JIA-ERA patients who reached clinical remission. This condition implies a reduction in JIA-ERA treatment costs, maintaining same effectivity and higher efficiency. <h3>Disclosure of Interest</h3> None Declared
Abstract P1-14-10: Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)
Authors: M Fernandez, I Calvo, N Martinez, M Herrero, Y Quijano, H Duran, M Garcia-Aranda, A Suarez, F Lopez-Rios, D Perez, S Perea, M Hidalgo, L Garcia-Estevez
Journal: Cancer Research (2012)

Abstract Background: B in combination with T has shown meaningful activity in patients (pts) with metastatic HER2-positive breast cancer. Pathological complete response (pCR) was defined as the absence of invasive disease at the time of histological study and there is a relationship between pCR and disease-free survival (DFS) and overall survival (OS). The complete pathological response rate is between 9 to 34% of patients receiving primary treatment prior to surgery with chemotherapy and when the Herceptin was administrated, a pCR of 39% was reached. AVANTHER is a Phase II trial of preoperative systemic therapy combining B with T and P in a weekly regimen in HER2 positive breast cancer to assess safety and efficacy of the combination. Methods: Pts with centrally-confirmed HER2− positive (IHC 3+ or FISH positive) breast cancer (stage II or III including locally advanced) received neoadjuvant chemotherapy (NC) with weekly P (80mg/m2/week) for 12 weeks in combination with weekly T (4mg/kg loading dose and 2 mg/kg maintenance) and B (15mg/kg every 3 weeks) for 4 cycles. After surgery all pts received T (1 year) and liposomal doxorubicin plus cyclophosphamide every 3 weeks (4 cycles); primary endpoint was rate of pathological complete response (pCR) in breast and axilla. For all patients, a tissue sample at baseline as well as at surgery was collected for biomarker analyses. Results: A total of 44 pts have been enrolled. Median tumor size: 3.9 cm. Nine (21%) pts had stage IIA; 19 (45%) stage IIB; 10 (24%) stage IIIA and 4 (10%) stage IIIB. Twenty-nine (69%) pts had estrogen positive receptors. Data from surgery of 42 patients from a total of 44 patients enrolled were presented in this abstract, but the final results will be present in the symposium. pCR was achieved in 18 (42.9%) pts. Safety and tolerability were good, with rare adverse events of grade 3 [1 (2.4%) episode of severe hypertension, 1 (2,4%) mucosal inflammation]. We presented the results of relationship between magnetic resonance imaging (MRI) and pCR that is one of the secondary objectives of the study. 100% of the patients without pathologic response had stable disease at resonance imaging. Of all patients who had pCR only 55.6% had complete radiological response. Conclusions: These data show that the combination of P with T and B without an anthracycline for 12 weeks is very effective as NC in HER2 positive breast cancer pts with a high rate of pCR and minimal side effects. And the MRI is useful for identifying the persistence of residual disease however it only predicts half of the complete pathological responses Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-10.
Effects of Beta-Adrenergic Blockade with Propranolol in Patients with Atrial Arrhythmias
Authors: Donald C. Harrison, John Robert Griffin, Thomas J. Fiene
Journal: New England Journal of Medicine (1965)

IN patients with atrial arrhythmias the ventricular rate is primarily determined by the frequency of atrial-impulse generation and the functional refractory period of the atrioventricular node. It is well known that the sympathetic nervous system has an important role in regulating both the frequency of cardiac-impulse generation and the functional refractory period of atrioventricular conduction.1 2 3 Both stimulation of the cardiac sympathetic nerves and exogenous administration of catechol amines increase the ventricular rate in animals and in patients.1 2 3 4 5 6 This response is thought to be due to stimulation of beta-adrenergic neuroreceptors in the system of classification proposed by Ahlquist.7 Several new blocking . . .
Stat BiteCancer Prevalence in Domestic Cats
Authors: H. Hayes
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Stat Bite Cancer Prevalence in Domestic Cats Get access Howard Hayes, D.V.M Howard Hayes, D.V.M Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 5, 2 March 1994, Page 335, https://doi.org/10.1093/jnci/86.5.335 Published: 02 March 1994
Abstract 4807: FOXD3 regulates Rnd3 and invasion in mutant BRAF melanoma cells
Authors: Pragati Dixit Katiyar, Ethan V. Abel, Andrew E. Aplin
Journal: Cancer Research (2010)

Abstract Melanoma occurs due to the transformation of melanocytes and is the deadliest form of skin cancer with an estimated 68,720 new cases and 8,650 deaths in 2009. During radial growth phase (RGP) that is confined to the epidermis and papillary dermis, melanoma is treatable by surgical excision. However, dermal invasion during the vertical growth phase (VGP) is associated with a worse prognosis. The mechanisms contributing to aberrant melanoma invasion are poorly elucidated. Activating mutations in BRAF (a serine kinase) are found in approximately 60% of melanoma cases. Mutant BRAF is required for the invasion and changes in actin cytoskeleton associated with invasion are in part controlled by Rnd3, a BRAF regulated Rho family GTPase. Melanocytes derive from the neural crest, a multipotent population of migratory cells. Pluripotency and self-renewal of neural crest cells is regulated by the transcription factor FOXD3. Since we have previously shown that BRAF inhibition results in up-regulation of FOXD3 and down-regulation of Rnd3, we examined the role of FOXD3 in regulation of Rnd3 in cellular migration and invasion. We used inducible lentiviral-based expression of FoxD3 in various mutant BRAF melanoma cell lines (WM793 and A375). Inducible expression of FoxD3 in WM793mFoxD3 and A375mFoxD3 was confirmed by western blot. Boyden chamber with or without matrigel coating and 3D tumor spheroid collagen assays were used to study cellular migration and invasion in a dermal mimetic microenvironment. We observed a significant decrease in the migration and invasion in WM793 (VGP) and A375 (metastatic) melanoma cell lines and a decreased spheroids formation in the soft agar colony formation assay after FoxD3 induction. This inhibition of migratory/ invasive properties correlated with a FOXD3-dependent down-regulation of Rnd3 both at protein and mRNA level. Our study for the first time showed that FoxD3 expression down-regulates Rnd3 that increased actin stress fiber formation and decreases migration, invasion and spheroids formation in the metastatic melanoma cells. This study is relevant to the current challenge of understanding mechanism of BRAF regulation of invasion and provides additional targets for therapeutic intervention for the effective treatment of melanoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4807.
Reactivation of Growth/Differentiation Factor 1 Contributes to the Chemopreventive Effect of 5-aza-2’deoxycytidine in Gastric Cancer
Authors: Wei-Qin Yang, May S.M. Li, Wei Kang, Li-Han Zeng, Haitian Wang, Anthony W. Chan, Enders K.W. Ng, Ka F. To, Francis K.L. Chan, Jun Yu, Michael W.Y. Chan, Joseph J.Y. Sung, Alfred S.L. Cheng
Journal: Clinical Gastroenterology and Hepatology (2014)
The Significance of Mediastinal Emphysema
Authors: W. P. VanderLaan, George Maresh
Journal: New England Journal of Medicine (1946)

SPONTANEOUS mediastinal emphysema is now a well recognized clinical entity to which considerable attention has been called. Although Hamman1 enumerated several routes by which air reaches the mediastinum, the finding of extensive mediastinal and subcutaneous emphysema may at times be too readily attributed to this relatively benign disorder and a serious underlying disease overlooked. It is the purpose of this paper to call attention to that possibility by presenting 2 cases. In Case 1 spontaneous mediastinal emphysema occurred twice, and at the time of recurrence mediastinal decompression became necessary. In Case 2 extensive mediastinal and subcutaneous emphysema was dependent on . . .
RESECCIÓN ENDOSCÓPICA DE LESIONES COLORRECTALES DE GRAN TAMAÑO. EXPERIENCIA DE UN ÚNICO CENTRO
Authors: D Martínez-Ares, I Martín Granizo, L Cid Gómez, JA Hermo Brión, A Martínez Turnes, J Martínez Cadilla, L De Castro Parga, P Estévez Boullosa, JI Rodríguez Prada
Journal: Endoscopy (2013)

Introducción: Las resección endoscópica en lesiones colorrectales de gran tamaño es una alternativa válida, teniendo en cuenta la no desdeñable morbi-mortalidad de la cirugía y la reconocida eficacia y seguridad del tratamiento endoscópico. Objetivos: La evaluación de la eficacia y seguridad en nuestro centro del tratamiento endoscópico de las lesiones colorrectales de gran tamaño (diámetro > 20 mm). Material y Método: Se incluyen prospectivamente los pacientes tratados en un periodo de 4 años (2009 – 2013). Se evalúan las características endoscópicas de las lesiones, la técnica de resección empleada, los resultados inmediatos y complicaiones de la misma y a 3, 12 y 24 meses. Se analiza la necesidad de cirugía, así como sus indicaciones. Se analizan los factores predictivos de fracaso en el tratamiento endoscópico. Resultados: Se han incluído 119 lesiones en 115 pacientes (65,2% varones). La mayoría son lesiones de colon derecho (33,6%) y recto (31,9%). El tamaño es de 36,8 mm. Mayoritariamente se emplea una técnica de resección fragmentada asistida por inyección submucosa. En 2 casos se realiza una resección asistida con bandas. La resección se interrumpe en 11 casos (9,2%), y se considera completa en el 84,2%. Tan sólo se registró una perforación, resuelta endoscópicamente. La tasa de curación a los 3 meses es del 74,4%, a los 12 meses del 90,1% y a los 24 meses del 100%. Se operaron 16 lesiones (13,4%), el 50% por fracaso del tratamiento endoscópico, y sólo un 25% por adenocarcinoma invasor en la pieza de resección. El principal factor predictivo del fracaso del tratamiento endoscópico es el “non lifting sign”, sólo en 3 casos (27%) debido a la presencia de adenocarcinoma invasor. Conclusiones: La resección endoscópica es altamente segura y eficaz en el tratamiento de las lesiones colorrectales de gran tamaño, suponiendo un gran ahorro en términos económicos y de morbi-mortalidad.
PTU-192 Time: prospective study combining endoscopic trimodal imaging and molecular endpoints to risk stratify Barrett's oesophagus
Authors: K M Shariff, M Di Pietro, D Boerwinkle, X Liu, P Lao Sirieix, E Walker, L Mills, E Telakis, S Slininger, M Visser, M O'Donovan, P Kaye, K Ragunath, J Bergman, R C Fitzgerald
Journal: Gut (2012)

<h3>Introduction</h3> Biomarkers have been proposed to improve risk stratification in Barrett9s oesophagus (BO), however molecular heterogeneity of BO can hamper detection of molecular changes in random biopsies. Use of Autofluorescence Imaging (AFI) within endoscopic Trimodal Imaging (ETMI) can improve dysplasia detection, but has high false positive rate. Aims of study were (a) validate biomarkers previously published in separate patient cohorts in single study (b) assess whether AFI can increase detection of biomarkers (c) combine ETMI and biomarkers to improve risk stratification of patients with BO. <h3>Methods</h3> Prospective European multicentre study. Each patient underwent ETMI with targeted biopsies on AFI positive (AFI+) areas and one AFI negative (AFI−) area, as well as random quadrantic biopsies. DNA content abnormalities (aneuploidy/tetraploidy); loss of heterozygosity (LOH) at 9p and 17p loci; RUNX3, HPP1 and p16 methylation; immunohistochemistry (IHC) for p53 and Cyclin A were tested on targeted biopsies. Each biomarker was correlated with the dysplasia and AFI status. <h3>Results</h3> 111 patients with 210 biopsy areas were included in the analysis (AFI+, n=120; AFI-, n=90). Univariate per-biopsy analysis showed that all biomarkers correlated with dysplasia (p&lt;0.05), with exception of 9p LOH. Multivariate analysis showed that aneuploidy, p53 IHC and Cyclin A (3 biomarker panel) were independently associated with dysplasia with an AUC=0.93 (95% CI 0.88 to 0.98) for any dysplasia and AUC=0.95 (95% CI 0.89 to 1) for HGD/early cancer (EC). AFI positivity significantly correlated with aneuploidy, p16 methylation, cyclin A and p53 staining (p&lt;0.05). After excluding dysplastic areas, aneuploidy (p=0.03) and p53 (p=0.04) staining retained statistical correlation with AFI positivity. Analysis of the 3 biomarker panel in patients with dysplasia showed significant biomarker enrichment in AFI+ compared to AFI- areas (p=0.001). Finally, 3 biomarker panel was used to predict prevalent dysplasia. Using a cut-off of ≥2 biomarkers, the panel when applied to AFI+ areas alone, showed sensitivity and specificity of 88% and 90% respectively for diagnosis of HGD/EC, and 64% and 96% respectively for diagnosis of any dysplasia, compared to overall histology. <h3>Conclusion</h3> AFI increases detection rate for molecular biomarkers. A panel of 3 molecular biomarkers on a small number of AFI targeted biopsies can efficiently predict the dysplasia status and potentially inform therapeutic management of patients with BE. <h3>Competing interests</h3> None declared.
F-18 FDG PET/CT Findings of a Case of Sacral Nerve Root Neurolymphomatosis That Occurred During Chemotherapy
Authors: Kazuyoshi Suga, Kawakami Yasuhiko, Naofumi Matsunaga, Toshiaki Yujiri, Tatsuki Nakazora, Kouichi Ariyoshi
Journal: Clinical Nuclear Medicine (2010)

Neurolymphomatosis (NL) is a rare, unique subtype of lymphomatous infiltration of peripheral nerves. Clinical/radiologic diagnosis of NL is challenging. We report F-18 FDG PET/CT findings of a case of breast diffuse large B-cell lymphoma, in which NL developed regardless of regression of systemic lesions during induction chemotherapy. FDG PET/CT showed characteristic findings of well-demarcated, linear abnormal FDG uptake along a sacral vertebral foramen, leading to diagnosis of NL, with the finding of thickened nerve roots on magnetic resonance imaging. Altered chemotherapeutic regimen resulted in disappearance of these abnormal FDG uptake, with recovery of neurologic symptoms. Peripheral nerve NL may occur during chemotherapy, and FDG PET/CT can be a useful imaging modality in diagnosis and monitoring of therapeutic response of this disease.
Color Duplex Ultrasonography in the Diagnosis of Temporal Arteritis
Authors: Wolfgang A. Schmidt, Helga E. Kraft, Klaus Vorpahl, Lutz Völker, Erika J. Gromnica-Ihle
Journal: New England Journal of Medicine (1997)

The diagnosis of temporal arteritis usually requires a biopsy of the temporal artery. We examined the usefulness of color duplex ultrasonography in patients suspected of having temporal arteritis.In this prospective study, all patients seen in the departments of rheumatology and ophthalmology from January 1994 to October 1996 who had clinically suspected active temporal arteritis or polymyalgia rheumatica were examined by duplex ultrasonography. The final diagnoses, made according to standard criteria, were temporal arteritis in 30 patients, 21 with biopsy-confirmed disease; polymyalgia rheumatica in 37; and negative histologic findings and a diagnosis other than temporal arteritis or polymyalgia rheumatica in 15. We also studied 30 control patients matched for age and sex to the patients with arteritis. Two ultrasound studies were performed and read before the biopsies; one ultrasonographer was unaware of the clinical information.In 22 (73 percent) of the 30 patients with temporal arteritis, ultrasonography showed a dark halo around the lumen of the temporal arteries. The halos disappeared after a mean of 16 days (range, 7 to 56) of treatment with corticosteroids. Twenty-four patients (80 percent) had stenoses or occlusions of temporal-artery segments, and 28 patients (93 percent) had stenoses, occlusions, or a halo. No halos were identified in the 82 patients without temporal arteritis; 6 (7 percent) had stenoses or occlusions. For each of the three types of abnormalities identified by ultrasonography, the interrater agreement was > or =95 percent.There are characteristic signs of temporal arteritis that can be visualized by color duplex ultrasonography. The most specific sign is a dark halo, which may be due to edema of the artery wall. In patients with typical clinical signs and a halo on ultrasonography, it may be possible to make a diagnosis of temporal arteritis and begin treatment without performing a temporal-artery biopsy.
Lymphoscintigraphy of Lower Limb Edema
Authors: Heather Zimmerman, Chris Kon Fessa, Monica Anne Rossleigh, Eva Alina Wegner
Journal: Clinical Nuclear Medicine (2012)

Lymphedema of the lower limbs is a well-known chronic condition. The cause of lymphedema can be either primary or secondary. Lymphoscintigraphy is a simple and reliable method for evaluation of lymphatic function. We illustrate the different lymph drainage patterns in 4 cases of lower limb edema, with either primary or secondary causes. In all cases, planar images were obtained after bipedal administration of 99mTc antimony sulfur colloid.
Amyand's Hernia
Authors: Ashkan A Malayeri, Stanley S Siegelman
Journal: New England Journal of Medicine (2011)

An 84-year-old man presented with a 5-day history of swelling and discomfort in the right inguinal region, which was followed by generalized abdominal pain, nausea, and vomiting. CT of the abdomen revealed an inflamed appendix within an indirect inguinal hernia.
PRESENTING CHARACTERISTICS AND OUTCOMES OF PAINLESS TYPE A AORTIC DISSECTION
Authors: Matthew Kolevar, Thomas Gleason, Arturo Evangelista, Himanshu Patel, Marek Ehrlich, Kevin Harris, Stuart Hutchison, Mark Peterson, Truls Myrmel, Eduardo Bossone, Daniel Montgomery, G. Chad Hughes, Kevin Greason, Eric Isselbacher, Christoph Nienaber, Kim Eagle
Journal: Journal of the American College of Cardiology (2015)
Families win right to compensation over CJD
Authors: C. Dyer
Journal: BMJ (1998)

Eight families whose relatives contracted the fatal Creutzfeldt-Jakob disease after being treated with human growth hormone in childhood won the right last week to compensation from the UK government likely to total more than £1m ($1.6m).

The victory brings to 20 the number of growth hormone CJD cases in which the government will have to pay compensation as a result of court rulings. Among the eight families whose claims were successful last week are the widow and three children of Neil Kreibich, an orthopaedic surgeon who died of CJD in 1997 aged 37.

Mr Justice Morland, the judge handling the litigation, ruled in 1996 that the Medical Research Council (MRC), which ran the growth hormone programme from 1959, was negligent from 1 July 1977 in …
OP0154 Chemerin and Knee Osteoarthritis: Effects on Inflammation and Cartilage Destruction
Authors: S. Abou-Raya, A. Abou-Raya, T. Khadrawi, M. Helmii
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Obesity is one of the main risk factors for knee osteoarthritis (OA). Fat tissue produces systemic inflammatory mediators, adipokines, which have a critical role in the development of OA. Chemerin is a chemokine that, through the engagement of its counter-receptor, ChemR23, attracts pro-inflammatory cells and IL-1<i>β</i>, along with other adipokines and glucocorticoids, is able to modulate the expression of this adipokine. Furthermore, stimulation of ChemR23 increases the production of pro-catabolic cytokines and matrix metalloproteinases. <h3>Objectives</h3> To determine serum chemerin levels and to evaluate the association of chemerin with inflammation and disease severity in older adults with knee OA. <h3>Methods</h3> 184 patients with clinical and radiographic criteria of primary knee OA diagnosed according to the criteria of the American College of Rheumatology and 96 age-sex-body mass index (BMI) matched healthy volunteers were recruited in this study. Disease severity assessment was performed using the Kellgren and Lawrence (KL) grading system. OA patients were defined as having radiographic knee OA of KL grade ≥2 in at least one knee. Controls were defined as having no radiographic knee OA as indicated by KL grades of 0 for both knees. The grading of the worst affected knee in each patient was used for data analysis. All participants underwent a full clinical examination including BMI calculation. Serum samples were obtained and levels of Chemerin, MMP-1, MMP-3, IL-1 and IL-6 were measured using commercial enzyme-linked immunosorbent assay (ELISA). Levels of C-reactive protein (CRP) and tumour necrosis factor (TNF)-alpha were also assessed. <h3>Results</h3> Chemerin levels in serum were significantly higher in patients compared to controls, p &lt; 0.01. Chemerin levels in knee OA patients correlated with disease severity as assessed by KL grading criteria. Chemerin levels correlated positively with biomarkers of OA, that is, MMP-1 (r = 0.555, p&lt; 0.01) and MMP-3 (r = 0.347, &lt; 0.01), IL-1 (r = 0.413, p&lt; 0.001), IL-6 (r = 0.432, P &lt; 0.01) and TNF-alpha (r = 0.537, p&lt; 0.05) respectively. Furthermore, there was a positive correlation between chemerin and BMI (r = 0.575, p&lt; 0.01). <h3>Conclusions</h3> The findings of this study show that in patients with knee OA, chemerin is associated with obesity, disease severity, inflammation and cartilage destruction. The implication of these findings is that chemerin may be a novel molecule involved in the pathogenesis and progression of OA. Chemerin may be regarded as a surrogate biomarker for severity of OA. Further studies targeting this adipokine may offer new hope for patients with knee OA. <h3>Disclosure of Interest</h3> None Declared